Overview

Pharmacodynamic Study of BKM120 in Breast Cancer

Status:
Completed

Trial end date:
2014-02-01

Target enrollment:

Participant gender:

Summary

BKM120 is a potent and highly specific oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, currently under investigation in a first-in-man study in patients with advanced solid tumors (wild type and PIK3CA-mutated). Consistent, dose-dependent pharmacodynamic activity has been demonstrated and clear signs of anti-tumor activity have been seen with BKM120.

Phase:

Early Phase 1

Details

Lead Sponsor:

Sofia Perea, Director Clinical Trials Unit.

Collaborator:

Novartis